Granulocyte death regulation by naturally occurring autoantibodies

Advances in Experimental Medicine and Biology

Volumn 750, Issue , 2012, Pages 157-172

  Von Gunten, Stephan ^a   Simon, Hans Uwe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CD161 ANTIGEN; CD33 ANTIGEN; CELL PROTEIN; FAS ANTIBODY; FAS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 5; NERVE GROWTH FACTOR; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE SHP 1; SIGLEC 8; SIGLEC 9; TUMOR NECROSIS FACTOR; TYROSINE; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; FAS PROTEIN, HUMAN; LECTIN; LEUKOCYTE ANTIGEN; SIGLEC8 PROTEIN, HUMAN; SIGLEC9 PROTEIN, HUMAN;

ALLERGIC DISEASE; ANTIBODY AFFINITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CELL ADHESION; CELL EXPANSION; CELL PROLIFERATION; CELL VIABILITY; CHURG STRAUSS SYNDROME; COMPLEX FORMATION; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; EOSINOPHIL; GRANULOCYTE; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEPSIS; TARGET CELL; UPREGULATION; CELL COUNT; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTIGENS, CD; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; APOPTOSIS; AUTOANTIBODIES; CELL COUNT; GRANULOCYTES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LECTINS; SIGNAL TRANSDUCTION;

EID: 84866791952     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3461-0_12     Document Type: Article

References (70)

1. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 30:180-92. doi:10.1016/j.immuni.2009.01.001 PMID:19239902
2. Simon HU. Regulation of eosinophil and neutrophil apoptosis-similarities and differences. Immunol Rev 179:156-62. doi:10.1034/j.1600-065X.2001.790115.x PMID:11292018
3. Simon HU. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev 2003; 193:101-10. doi:10.1034/j.1600-065X.2003.00038.x PMID:12752675 (Pubitemid 36688044)
4. Sprent J, Tough DF. T cell death and memory. Science 2001; 293:245-8. doi:10.1126/science.1062416 PMID:11452113 (Pubitemid 32694730)
5. von Gunten S, Simon HU. Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes. FASEB J 2006; 20:601-5. doi:10.1096/fj.05-5401hyp PMID:16581967 (Pubitemid 44933303)
6. von Gunten S, Bochner BS. Basic and clinical immunology of Siglecs. Ann N Y Acad Sci 2008; 1143:61-82. doi:10.1196/annals.1443.011 PMID:19076345
7. Nutku E, Hudson SA, Bochner BS. Mechanism of Siglec-8-induced human eosinophil apoptosis: Role of caspases and mitochondrial injury. Biochem Biophys Res Commun 2005; 336:918-24. doi:10.1016/j. bbrc.2005.08.202 PMID:16157303 (Pubitemid 41338356)
8. von Gunten S, Yousefi S, Seitz M et al. Siglec-9 transduces apoptotic and non-apoptotic death signals into neutrophils depending on the pro-inflammatory cytokine environment. Blood 2005; 106:1423-31. doi:10.1182/blood-2004-10-4112 PMID:15827126 (Pubitemid 41129611)
9. von Gunten S, Bochner BS. Expression and function of Siglec-8 in human eosinophils, basophils, and mast cells. In: Pawankar R, Holgate ST, Rosenwasser LJ, eds. Allergy Frontiers: Classification and pathomechanisms. Vol. 2. Tokyo, Japan: Springer; 2009:297-313.
10. von Gunten S, Simon HU. Cell death modulation by intravenous immunoglobulin. J Clin Immunol 2010; 30(Suppl 1):S24-30. doi:10.1007/s10875-010- 9411-8 PMID:20405180
11. von Gunten S, Simon HU. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: Implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 7:453-6. doi:10.1016/j.autrev. 2008.03.015 PMID:18558361
12. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-55. doi:10.1056/NEJMra993360 PMID:11547745
13. Negi VS, Elluru S, Sibéril S et al. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27:233-45. doi:10.1007/s10875-007-9088-9 PMID:17351760 (Pubitemid 46790823)
14. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513. doi:10.1146/annurev.immunol.26.021607. 090232 PMID:18370923
15. Simon HU, Späth PJ. IVIG - mechanisms of action. Allergy 2003; 58:543-52. doi:10.1034/ j.1398-9995.2003.00239.x PMID:12823109 (Pubitemid 36831306)
16. von Gunten S, Vogel M, Schaub A et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2007; 119:1005-11. doi:10.1016/j.jaci.2007.01.023 PMID:17337295
17. von Gunten S, Simon HU. Autophagic-like cell death in neutrophils induced by autoantibodies. Autophagy 3:67-8. PMID:17102587
18. von Gunten S, Schaub A, Vogel M et al. Immunological and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin (IVIg) preparations. Blood 2006; 108:4255-9. doi:10.1182/ blood-2006-05-021568 PMID:16902148 (Pubitemid 44913301)
19. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3. doi:10.1126/science.282.5388.490 PMID:9774279 (Pubitemid 28483679)
20. Altznauer F, von Gunten S, Späth P et al. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003; 112:1185-90. doi:10.1016/j. jaci.2003.09.045 PMID:14657880 (Pubitemid 37550013)
21. Prasad NK, Papoff G, Zeuner A et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161:3781-90. PMID:9759905
22. Sooryanarayana, Prasad N, Bonnin E et al. Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun 1999; 264:896-901. doi:10.1006/bbrc.1999.1592 PMID:10544027
23. Reipert BM, Stellamor MT, Poell M et al. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang 2008; 94:334-41. doi:10.1111/j.1423-0410.2008.001036.x PMID:18266779 (Pubitemid 351535734)
24. Nutku E, Aizawa H, Hudson SA et al. Ligation of Siglec-8: A selective mechanism for induction of human eosinophil apoptosis. Blood 2003; 101:5014-20. doi:10.1182/blood-2002-10-3058 PMID:12609831 (Pubitemid 36857767)
25. Crocker PR, Clark EA, Filbin M et al. Siglecs: A family of sialic-acid binding lectins. Glycobiology 1998; 8:v-vi. PMID:9498912
26. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7:255-66. doi:10.1038/nri2056 PMID:17380156 (Pubitemid 46480955)
27. Varki A, Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 2006; 16:1R-27R. doi:10.1093/glycob/cwj008 PMID:16014749 (Pubitemid 43009801)
28. O'Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009; 30:240-8. doi:10.1016/j.tips.2009.02.005 PMID:19359050
29. Yousefi S, Simon HU. SHP-1: A regulator of neutrophil apoptosis. Semin Immunol 2003; 15:195-9. doi:10.1016/S1044-5323(03)00033-2 PMID:14563118 (Pubitemid 38155826)
30. Daigle I, Yousefi S, Colonna M et al. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 2002; 8:61-7. doi:10.1038/nm0102-61 PMID:11786908 (Pubitemid 34101730)
31. Rashmi R, Bode BP, Panesar N et al. Siglec-9 and SHP-1 are differentially expressed in neonatal and adult neutrophils. Pediatr Res 2009; 66:266-71. doi:10.1203/PDR.0b013e3181b1bc19 PMID:19542910
32. Cao H, de Bono B, Belov K et al. Comparative genomics indicates the mammalian CD33rSiglec locus evolved by an ancient large-scale inverse duplication and suggests all Siglecs share a common ancestral region. Immunogenetics 2009; 61:401-17. doi:10.1007/s00251-009-0372-0 PMID:19337729
33. Varki A. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 2007; 446:1023-9. doi:10.1038/ nature05816 PMID:17460663 (Pubitemid 46676064)
34. Vimr E, Lichtensteiger C. To sialylate, or not to sialylate: That is the question. Trends Microbiol 2002; 10:254-7. doi:10.1016/S0966-842X(02)02361-2 PMID:12088651 (Pubitemid 34671142)
35. Angata T. Molecular diversity and evolution of the Siglec family of cell-surface lectins. Mol Divers 2006; 10:555-66. doi:10.1007/s11030-006-9029-1 PMID:16972014 (Pubitemid 44885232)
36. Cao H, Crocker PR. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology 2011; 132:18-26. doi:10.1111/j.1365-2567.2010.03368.x PMID:21070233
37. Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/ AIRM) and Siglec-9. J Biol Chem 2004; 279:43117-25. doi:10.1074/jbc.M403538200 PMID:15292262 (Pubitemid 39372207)
38. Avril T, Floyd H, Lopez F et al. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol 2004; 173:6841-9. PMID:15557178 (Pubitemid 39541070)
39. Carlin AF, Uchiyama S, Chang YC et al. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 2009; 113:3333-6. doi:10.1182/blood- 2008-11-187302 PMID:19196661
40. von Gunten S, Jakob S, Geering B et al. Different patterns of Siglec-9-mediated neutrophil death responses in septic shock. Shock 2009; 32:386-92. doi:10.1097/SHK.0b013e3181a1bc98 PMID:19295491
41. Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 2001; 179:5-15. doi:10.1034/j.1600-065X.2001.790101.x PMID:11292027 (Pubitemid 32171269)
42. Simon HU, Blaser K. Inhibition of programmed eosinophil death: A key pathogenic event for eosinophilia? Immunol Today 1995; 16:53-5. doi:10.1016/0167-5699(95)80086-7 PMID:7888065
43. Simon HU. Novel therapeutic strategies via the apoptosis pathways to resolve chronic eosinophilic inflammation. Cell Death Differ 1996; 3:349-56. PMID:17180105
44. Simon HU, Yousefi S, Schranz C et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997; 158:3902-8. PMID:9103460 (Pubitemid 127488750)
45. Simon H-U, Rothenberg ME, Bochner BS et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45-9. doi:10.1016/j.jaci.2010.03.042 PMID:20639008
46. Klion AD, Bochner BS, Gleich GJ et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol 2006; 117:1292-302. doi:10.1016/j.jaci.2006.02.042 PMID:16750989 (Pubitemid 43795762)
47. Simon HU. Eosinophil apoptosis-pathophysiologic and therapeutic implications. Allergy 2000; 55:910-5. doi:10.1034/j.1398-9995.2000.055010910.x PMID:11030370
48. Bochner BS. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 2009; 39:317-24. doi:10.1111/j.1365-2222.2008.03173.x PMID:19178537
49. Yokoi H, Choi OH, Hubbard W et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol 2008; 121:499-505. doi:10.1016/j.jaci.2007.10.004 PMID:18036650 (Pubitemid 351215177)
50. Zhang M, Angata T, Cho JY et al. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 2007; 109:4280-7. doi:10.1182/blood-2006-08-039255 PMID:17272508 (Pubitemid 46743394)
51. Zimmermann N, McBride ML, Yamada Y et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 2008; 63:1156-63. doi:10.1111/j.1398-9995.2008.01709.x PMID:18699932
52. Cho JY, Song DJ, Pham A et al. Chronic OVA allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13. Respir Res 2010; 11:154. doi:10.1186/1465-9921-11-154 PMID:21040544
53. Song DJ, Cho JY, Lee SY et al. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol 2009; 183:5333-41. doi:10.4049/jimmunol.0801421 PMID:19783675
54. Song DJ, Cho JY, Miller M et al. Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. Clin Immunol 2009; 131:157-69. doi:10.1016/j. clim.2008.11.009 PMID:19135419
55. Vassina EM, Yousefi S, Simon D et al. cIAP-2 and survivin contribute to cytokine-mediated delayed eosinophil apoptosis. Eur J Immunol 2006; 36:1975-84. doi:10.1002/eji.200635943 PMID:16761316 (Pubitemid 44089062)
56. Plötz SG, Simon HU, Darsow U et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349:2334-9. doi:10.1056/NEJMoa031261 PMID:14668459 (Pubitemid 37521232)
57. Schaub A, von Gunten S, Vogel M et al. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy 2011; 66:1030-7. doi: 10.1111/j.1398-9995.2011.02579.x PMID:21385183
58. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994; 139:159-72. doi:10.1111/j.1600-065X.1994. tb00861.x PMID:7927410 (Pubitemid 24232676)
59. Jerne NK. Toward a network theory of the immune system. Ann Immunol 1974; 125C:373-89. PMID: 4142565
60. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-62. doi:10.1126/science.7510905 PMID:7510905 (Pubitemid 24131584)
61. Cascino I, Fiucci G, Papoff G et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154:2706-13. PMID:7533181
62. Tsurikisawa N, Taniguchi M, Saito H et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92:80-7. doi:10.1016/S1081-1206(10)61714-0 PMID:14756469 (Pubitemid 38113636)
63. Takigawa N, Kawata N, Shibayama T et al. Successful treatment of a patient with severe Churg-Strauss syndrome by a combination of pulse corticosteroids, pulse cyclophosphamide, and high-dose intravenous immunoglobulin. J Asthma 2005; 42:639-41. doi:10.1080/02770900500263822 PMID:16266953 (Pubitemid 41609529)
64. Khan S, Sewell WA. Risks of intravenous immunoglobulin in sepsis affect trial design. Ann Intern Med 147:813-4. PMID:18056670
65. Buenz EJ, Howe CL. Appropriate use of intravenous immunoglobulin in neonatal neutropenia. J Perinatol 27:196-7. doi:10.1038/sj.jp.7211660 PMID:17314992
66. Lassiter HA, Bibb KW, Bertolone SJ et al. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol 1993; 15:120-3. doi:10.1097/00043426-199302000-00019 PMID:8447553 (Pubitemid 23061723)
67. Tam DA, Morton LD, Stroncek DF et al. Neutropenia in a patient receiving intravenous immune globulin. J Neuroimmunol 1996; 64:175-8. doi:10.1016/0165- 5728(95)00167-0 PMID:8632059 (Pubitemid 26094633)
68. Berkovitch M, Dolinski G, Tauber T et al. Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Int J Immunopharmacol 1999; 21:411-5. doi:10.1016/S0192-0561(99)00020-X PMID:10405875 (Pubitemid 29248895)
69. Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. J Pediatr Hematol Oncol 2005; 27:145-7. doi:10.1097/01. mph.0000155871.26380.84 PMID:15750446
70. Matsuda M, Hosoda W, Sekijima Y et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol 2003; 26:306-11. doi:10.1097/00002826-200311000-00009 PMID:14646610 (Pubitemid 37505437)